Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.69 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.62 |
| ▸ | MGLL | Q99685 | 3/20 | 0.55 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.53 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.53 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1812470 | 0.99 | HRH3 (0.68) | HRH3L3MBTL3L3MBTL1MGLLMBTD1 | |
| SCHEMBL1812564 | 0.85 | L3MBTL3 (0.57) | HRH3L3MBTL3L3MBTL1MGLLMBTD1 | |
| SCHEMBL1809657 | 0.85 | MGLL (0.64) | HRH3L3MBTL3L3MBTL1MGLLMBTD1 | |
| SCHEMBL12625739 | 0.83 | L3MBTL3 (0.55) | HRH3L3MBTL3L3MBTL1MGLLMBTD1 | |
| SCHEMBL1812832 | 0.83 | HRH3 (0.72) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL1810184 | 0.83 | L3MBTL1 (0.57) | HRH3L3MBTL3L3MBTL1MGLLMBTD1 | |
| SCHEMBL1811396 | 0.83 | L3MBTL3 (0.57) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL1809624 | 0.83 | HRH3 (0.59) | HRH3L3MBTL3L3MBTL1MGLLMBTD1 | |
| SCHEMBL1812779 | 0.83 | MGLL (0.66) | HRH3L3MBTL3L3MBTL1MGLLMBTD1 | |
| SCHEMBL1812903 | 0.83 | MGLL (0.66) | HRH3L3MBTL3L3MBTL1MGLLMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | claimed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | claimed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2074088-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008045371-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045371-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | HNMT, HRH4, HRH3 | HRH3 3/4885L3MBTL3 2875/4885L3MBTL1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.